Welcome to HitGen

News

Get up to date with the latest HitGen articles and join us in the events

Press Release

  • 08 April 2024
    Vernalis announces a drug discovery collaboration with C4X Discovery in inflammatory disease
  • 26 March 2024
    HitGen Partners with LabCentral / BioLabs / MBC BioLabs to Accelerate Biotechnology Discovery
  • 21 February 2024
    Hox Therapeutics and Vernalis announce a drug discovery collaboration in oncology
  • 13 November 2023
    Get ready for the end-of-year sale! Discover the future of drug discovery with OpenDEL™ and save 20% off!
  • 27 October 2023
    Infographic | HitGen FY2023 Q3 Report
  • 19 October 2023
    Venture forces invest millions in new type of treatment for particularly aggressive form of cancer
Read More

Coverage

  • July 15, 2020

    Jin LI – Chairman & CEO, HitGen, China

    PHARMA BOARDROOM Dr Jin Li explains Chinese firm HitGen’s unique drug discovery technology platform, how its ability to screen billions of molecules has the potential to significantly increase success rates in early drug discovery, and the next steps for the company’s expansion. "By now, we have a platform of over 500 billion small molecules, and in terms of published numbers, we probably have the largest DEL collections in the world. By the end of this year, we hope to have built a DEL of over one trillion small molecules!"
  • May 07, 2020

    New economy business becomes a growing driver of city development

    China Daily, Yuan Shenggao 2020-05-07 HitGen, a local biopharmaceutical company, was listed on the science and technology innovation board at the Shanghai Stock Exchange in mid-April, and is the first company in southwestern China to appear on the board. The company, founded in 2012, provides research services for the early stages of drug discovery using its core DNA encoded compound library technology. It has established partnerships with multinational drug and biomedicine companies such as Pfizer, Johnson & Johnson, MSD and Sanofi. Li Jin, chairman and general manager of HitGen, said it will expand investment into DNA encoded compound library technology and business, to promote research and development of drugs.
  • April 29, 2020

    Chinese biotech firm uses DNA to discover new drugs

    CGTN, By Wei Lynn Tang HitGen Inc., a Chengdu-based biotechnology company that has listed on China's Science and Technology Innovation Board on April 16, raising some 118 million U.S. dollars. According to the company's listing prospectus, 75 percent of its listing net proceeds will be used for a new molecular design, construction, and application platform construction project, with the remaining funds for a new drugs research and development project. According to the company's listing prospectus, 75 percent of its listing net proceeds will be used for a new molecular design, construction, and application platform construction project, with the remaining funds for a new drugs research and development project. Li Jin, chairman and CEO of HitGen, said the company's top priority is to continue to invest in its core technology – the DEL technology – to make progress in its drug discovery programs.
Read More

Events

December 20-January 01
BSBE Guest Seminar丨Dr. Dengfeng DOU from HitGen Inc.
November 03-January 01
See you in Shanghai! HitGen Pharmaceuticals Inc. to attend the 5th China International Import Expo
January 11-01
Meet us in BIOTECH SHOWCASE™2022 in virtual!
June 10-18
BIO International Digital Convention 2021
October 13-January 01
“Evolving DNA-Encoded Library (DEL) technology to meet drug discovery needs” webinar offered by HitGen and Endpoints News coming up on Friday 20th October
January 12-01
Meet you in JPM 2022
June 30-30
Webinar: Advancing Innovative Drug Discovery by DNA Encoded Library (DEL) and FBDD/SBDD methods
Read More

Industry News

  • 03.20
    DEL for Unconventional Applications
    The advancement of DNA Encoded Library (DEL) technology has been significant in recent decades. Beyond its conventional role in small molecule drug discovery, its integration into emerging fields has begun to garner increased interest. This can be attributed to its large chemical space, abundant Structure-Signal Relationship (SSR) data, and inherent DNA conjugation properties. In this context, we will explore alternative applications of DEL technology. It is postulated that with the continuous expansion of the DEL field and technological progression, more applications are yet to be unveiled.
  • 03.07
    DEL for Kinases
    As one of the largest and most functionally diverse gene families, kinases have been recognized as key regulators/mediators of biological signaling networks. More than 30% of drug development efforts target these enzymes in the past two decades. As of January 2024, more than 90 small molecule kinase drugs have been approved by the US Food and Drug Administration (FDA), with approximately 200 orally available protein kinase inhibitors in clinical trials. These compounds have had a significant impact on the treatment of both oncological and non-oncological conditions.
  • 11.27
    DEL for Covalent Ligand Discovery
    Although many covalent drugs were serendipitously discovered historically, covalent inhibitors were in general discouraged due to the concerns over their interference with biological assays and potential lack of selectivity. Over the past decades, rational design of covalent inhibitors has gained traction and garnered increased interest, particularly due to their stronger potency, prolonged target engagement, increased selectivity, and effectiveness to some drug-resistance mutants to reversible inhibitors.
  • 11.14
    DNA-Encoded Library (DEL) for Compound Optimization & Expansion
    DNA-encoded library (DEL) technology represents a revolutionary method in drug discovery. Unlike conventional approaches, DEL enables unparalleled exploration of chemical space, leading to the rapid identification of novel potent compounds.
Read More

Thanks for reading!

For more details on how we can advance your innovative drug discovery projects
验证码
By submitting your information, you acknowledge having received, read and understood our Privacy Notice as made available above.

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information